Education
About Us
Working with TipRanks
Follow Us
CryoPort Inc (CYRX)
NASDAQ:CYRX
Top Page
CryoPort
(NASDAQ:CYRX)
Select Model
Select Model
Rating:57Neutral
Price Target:
$8.50
▼(-7.71% Downside)
Action:ReiteratedDate:03/06/26
The score is held back primarily by weak underlying financial quality (ongoing operating losses and negative, deteriorating cash flow) and bearish technical momentum. These are partially offset by a low P/E valuation and a positive earnings-call outlook with growth guidance and expected adjusted EBITDA improvement into H2 2026.
Positive Factors
Revenue Growth in Key Segments
Strong growth in critical segments like Life Sciences Services and Products indicates robust demand and market expansion, supporting long-term revenue stability.
Strategic Partnerships
The partnership with DHL enhances CryoPort's logistics capabilities and market reach in APAC and EMEA, strengthening its competitive position.
New Product Launches
Introducing advanced cryogenic systems supports product diversification and technological leadership, driving future growth and market differentiation.
Negative Factors
Declining Revenue Growth
A negative revenue growth trend poses a risk to long-term financial health, indicating challenges in maintaining market share and operational efficiency.
Cash Flow Challenges
Negative cash flow highlights inefficiencies in operations and limits the company's ability to invest in growth opportunities, impacting financial stability.
High Operating Expenses
Elevated operating expenses reduce profitability, challenging the company's ability to improve margins and sustain long-term financial performance.
CryoPort (CYRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$404.83M
Dividend YieldN/A
Average Volume (3M)690.07K
Price to Earnings (P/E)6.8
Beta (1Y)1.17
Revenue Growth-15.86%
EPS Growth66.42%
CountryUS
Employees1,090
SectorIndustrials
Sector Strength72
IndustryIntegrated Freight & Logistics
Share Statistics
EPS (TTM)-0.27
Shares Outstanding49,856,136
10 Day Avg. Volume860,552
30 Day Avg. Volume690,069
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.96
Price to Sales (P/S)2.73
P/FCF Ratio-19.21
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue2.20
Enterprise Value/Gross Profit4.66
Enterprise Value/Ebitda-50.59
Forecast
1Y Price Target
$13.40Price Target Upside45.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$189.50M
CryoPort Business Overview & Revenue Model
Company DescriptionCryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
How the Company Makes MoneyCryoPort generates revenue primarily through its logistics services, particularly the shipping and storage of temperature-sensitive biological materials. Key revenue streams include fees for CryoPort Express® shipping services, which are charged based on the volume and distance of shipments. Additionally, the company earns income from long-term contracts with pharmaceutical and biotechnology companies, which require ongoing logistics support for clinical trials and commercial product distribution. Significant partnerships with leading biopharmaceutical firms enhance its market position and contribute to consistent revenue growth. The company also benefits from increasing demand for advanced therapies, including cell and gene therapies, which require specialized logistics solutions.
CryoPort Key Performance Indicators (KPIs)
CryoPort Earnings Call Summary
Earnings Call Date:Mar 03, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational momentum and clear growth drivers: revenue exceeded guidance, commercial cell and gene therapy and BioStorage/BioServices posted robust double-digit gains, the clinical pipeline is deep (86 Phase III, 361 Phase II) and product innovation continues. Management improved adjusted EBITDA by $12M and expects positive adjusted EBITDA in H2 2026, while setting 2026 revenue guidance of $190M–$194M. Offsetting risks are modest near-term headwinds: slower quarterly product growth, short-term costs from expedited site buildouts, gradual realization of DHL partnership benefits, and macro/regulatory uncertainties. Overall, highlights substantially outweigh the manageable lowlights, supporting an optimistic near- to mid-term outlook.Q4-2025 Updates
Positive Updates
Full-Year Revenue Above Guidance
Revenue from continuing operations of $176.2 million for fiscal 2025, exceeding the high end of prior guidance.
Strong Commercial Cell & Gene Therapy Growth
Commercial cell and gene therapy revenue increased 29% year-over-year to a record $33.4 million and represented ~20% of total revenue for 2025.
Clinical Trial Revenue Expansion
Clinical trial revenue grew 14% year-over-year to $47.1 million; supported a record 760 clinical trials (net increase of 59) and 20 commercial therapies worldwide.
Life Sciences Services Momentum
Life Sciences Services revenue grew 18% year-over-year in 2025, with BioStorage/BioServices up 22%, reflecting expanded scale and higher revenue per client.
Profitability Progress and Margin Improvement
Gross margin improved to 47% and adjusted EBITDA improved by $12 million year-over-year; company expects to achieve positive adjusted EBITDA in the second half of 2026.
Product Innovation and MVE Releases
Life Sciences Products (MVE) revenue grew 7% year-over-year; launched integrated condition monitoring with Cryoverse and the Fusion 800 Series self-sustaining cryogenic freezer, expanding addressable markets.
Strategic Partnerships and Capital Infusion
Completed strategic partnership and sale of CRYOPDP to DHL in 2Q25 (providing substantial capital infusion) and added partnerships with Cardinal Health and Parexel to broaden the ecosystem.
Robust Clinical-to-Commercial Pipeline and 2026 Guidance
Company is 'spring-loaded' with 86 Phase III and 361 Phase II clinical trials, anticipates ~13 BLA/MAA filings (2 already filed), 9 new approvals and 2 label/geographic expansions; 2026 revenue guidance of $190M–$194M (midpoint implying ~8.9% growth over 2025).
Negative Updates
Near-Term Product Growth Softening
MVE product revenue showed modest growth with 7% for the full year but only ~2% year-over-year in the fourth quarter; management now forecasts mid-single-digit growth for MVE in 2026 (7%–8%) rather than previously discussed higher ranges.
Delay Toward Adjusted EBITDA Positivity
Adjusted EBITDA positive was pushed out to H2 2026 due in part to investments and accelerated client-driven buildouts (e.g., rapid Belgium GMP kitting expansion), indicating short-term margin pressure despite a $12M improvement in adjusted EBITDA year-over-year.
Integration/Timing Risk with DHL Partnership
While the DHL transaction provides capital and strategic opportunity, management cautioned that realization of EMEA/APAC benefits will be gradual because of DHL's large, less-agile organizational structure.
Macro and Regulatory Uncertainty
Management cited macro volatility and regulatory unpredictability as downside risks to guidance, acknowledging unknowns that could affect timing and magnitude of growth despite a constructive industry outlook.
Limited Granularity in Segment Guidance
Company declined to provide detailed segmentation or specific assumptions (e.g., animal/reproductive health contribution, exact commercial vs. clinical revenue split for 2026), reducing visibility for precise modeling.
Short-Term Investment-Related Costs
Accelerated investments to capture client demand (e.g., Paris and California Global Supply Chain Centers, rapid Belgium buildout) may depress near-term profitability while positioning the company for longer-term revenue capture.
Company Guidance
Cryoport guided full‑year 2026 revenue of $190–$194 million (midpoint ~$192M, roughly +9% vs. 2025 continuing‑operations revenue of $176.2M) and reiterated it expects to achieve positive adjusted EBITDA in the second half of 2026; management also said it anticipates ~13 BLA/MAA filings (2 already filed), 9 new therapy approvals plus 2 label/geographic expansions (with 3 customer decisions expected in March–April), noting a “spring‑loaded” clinical pipeline of 760 supported trials (86 Phase III, 361 Phase II) and 20 commercial therapies, after 2025 results that included $33.4M in commercial cell & gene therapy revenue (+29% YoY, ~20% of Q4 revenue), $47.1M in clinical trial revenue (+14% YoY), Life Sciences Services revenue +18% (BioStorage/BioServices +22%), Life Sciences Products +7%, a 47% gross margin, and a $12M year‑over‑year improvement in adjusted EBITDA.CryoPort Financial Statement Overview
Summary
Reported profitability improved in 2025 with net income turning strongly positive and leverage improving, but fundamentals remain mixed: revenue declined, operating margin is still negative, and cash flow is persistently negative with worsening free cash flow—suggesting ongoing funding/execution risk until operations and cash generation improve.Income Statement
Profitability improved sharply in 2025 with net income turning strongly positive (about 40% margin), a major reversal from sizable losses in 2024. However, core operations remain challenged as operating profit is still negative in 2025 (about -21% margin), and revenue declined about 7% versus the prior year after modest growth in 2024. Gross margin is steady-to-improving (mid-to-high 40% range), but the combination of declining sales and ongoing operating losses keeps the income statement quality mixed.48
Neutral
Balance Sheet
The balance sheet looks reasonably supportive: debt-to-equity improved materially in 2025 (about 0.46) from 2024 (about 0.85), indicating deleveraging and better capital structure resilience. Equity is sizable relative to assets, and return on equity is positive in 2025, reflecting the year’s net income rebound. Offsetting this, leverage has been elevated in prior years and earnings volatility (losses in multiple years before 2025) raises the risk that balance-sheet strength could be tested if operating performance doesn’t stabilize.66
Positive
Cash Flow
Cash generation remains a clear weak spot: operating cash flow is negative in 2025 and 2024, and free cash flow is meaningfully negative across the period shown. Free cash flow deterioration in 2025 versus 2024 suggests the business is still consuming cash despite the reported net income recovery. Overall, the cash flow profile points to continued funding needs and execution risk until operating cash flow turns sustainably positive.34
Negative
| Breakdown | Dec 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 176.18M | 233.25M | 237.28M | 222.61M | 222.61M |
| Gross Profit | 83.05M | 99.33M | 103.87M | 96.58M | 96.58M |
| EBITDA | -11.65M | -66.36M | -6.19M | -248.91M | -248.91M |
| Net Income | 70.30M | -99.59M | -37.33M | -275.53M | -275.53M |
Balance Sheet | |||||
| Total Assets | 764.99M | 703.49M | 957.74M | 1.04B | 1.11B |
| Cash, Cash Equivalents and Short-Term Investments | 411.21M | 261.75M | 456.75M | 523.32M | 628.80M |
| Total Debt | 230.72M | 250.70M | 416.00M | 435.91M | 427.06M |
| Total Liabilities | 262.35M | 301.59M | 468.72M | 482.91M | 471.14M |
| Stockholders Equity | 502.64M | 401.90M | 489.02M | 555.84M | 641.83M |
Cash Flow | |||||
| Free Cash Flow | -25.02M | -33.58M | -45.66M | -26.05M | -16.88M |
| Operating Cash Flow | -8.58M | -16.32M | -757.00K | -1.85M | 8.13M |
| Investing Cash Flow | 250.32M | 176.81M | 36.05M | -59.68M | -469.25M |
| Financing Cash Flow | -21.07M | -161.53M | -23.80M | -39.17M | 564.34M |
CryoPort Technical Analysis
Neutral
9.21
Price Trends
9.20
Negative
9.26
Negative
8.77
Negative
Market Momentum
-0.28
Negative
48.35
Neutral
33.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYRX, the sentiment is Neutral. The current price of 9.21 is above the 20-day moving average (MA) of 8.26, above the 50-day MA of 9.20, and above the 200-day MA of 8.77, indicating a neutral trend. The MACD of -0.28 indicates Negative momentum. The RSI at 48.35 is Neutral, neither overbought nor oversold. The STOCH value of 33.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CYRX.
CryoPort Risk Analysis
CryoPort disclosed 33 risk factors in its most recent earnings report. CryoPort reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CryoPort Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $82.23B | 17.37 | 15.67% | 1.94% | 3.09% | 14.94% | |
73 Outperform | $18.86B | 10.88 | 13.94% | 2.98% | 12.89% | 3.12% | |
69 Neutral | $18.70B | 31.73 | 16.33% | 0.89% | -1.60% | 4.87% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
63 Neutral | $22.23B | 50.75 | 17.81% | ― | -0.30% | -11.02% | |
57 Neutral | $404.83M | 6.84 | 17.12% | ― | -15.86% | 66.42% | |
50 Neutral | $6.11B | 190.29 | 1.09% | ― | 16.94% | -14.01% |
* Industrials Sector Average
CYRX
CryoPort
8.12
2.28
39.04%
XPO
XPO
189.72
78.20
70.12%
FDX
FedEx
349.74
107.99
44.67%
JBHT
JB Hunt
197.64
52.19
35.88%
ZTO
ZTO Express
25.51
4.48
21.31%
GXO
GXO Logistics
53.24
12.40
30.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.